Trikafta, a CFTR modulator, is increasingly used to treat children with cystic fibrosis (CF), but its effects remain unclear. This study evaluated the cellular mechanisms of Trikafta in young children (< 11 years) with CF using a multi-omic approach. Seventeen children with CF (median age 8.4 years,...
ORGANISM(S): Homo sapiens (Human)